Renal Functions in Preeclamptic Pregnant Women Using Neutrophil Gelatinase-associated Lipocalin (NGAL) and Standard Renal Function Tests

June 8, 2025 updated by: Nihan Aydin Guzey

Evaluation of the Effect of Spinal Anesthesia-Induced Hypotension on Renal Functions in Preeclamptic Pregnant Women Using Neutrophil Gelatinase-associated Lipocalin (NGAL) and Standard Renal Function Tests

Acute kidney injury (AKI) is a significant postoperative complication. Risk factors for AKI include impaired renal perfusion, decreased functional renal reserve, as well as advanced age, peripheral arterial disease, diabetes mellitus, renovascular disease and congestive heart failure. Mean arterial pressure (MAP) below 55-60 mmHg has been associated with postoperative AKI. Traditional diagnostic criteria for AKI include increased serum creatinine levels and oliguria. However, creatinine levels do not rise until more than half of renal function is lost. Serum and urine NGAL levels rise earlier-within 24-48 hours-making it a promising early biomarker.

In our study, hypotension is defined as systolic blood pressure <100 mmHg or a >30% decrease in MAP. Patients requiring ephedrine under these conditions will be evaluated as the hypotension group and compared with non-hypotensive patients in terms of NGAL, BUN (blood urea nitrogen), creatinine, and GFR (Glomerular Filtration Rate) values at baseline and at the 4th postoperative hour.

Study Overview

Detailed Description

All patients were informed about the study in the preoperative period and written informed consent was obtained before the procedure. The following data were recorded: age, sex, weight, height, BMI (Body Mass Index), comorbidities, regular medications, ASA (American Society of Anesthesiologists) classification, gestational age, history of preeclampsia in previous pregnancies, hemodynamic values and laboratory results. After being admitted to the cesarean operating room, patients were monitored according to the ASA guidelines using standard monitoring methods (non-invasive arterial blood pressure measurements at 2-minute intervals, 3-lead ECG (Electrocardiogram) and pulse oximetry). A peripheral intravenous line was established via the dorsum of the hand and Ringer's lactate was infused at a rate of 10 mL/kg/h. All patients received oxygen via nasal cannula at a rate of 3-4 L/min.

Blood samples were collected from the patients before spinal anesthesia and at the 4th postoperative hour. The samples were centrifuged at 4000×g for 10 minutes in the biochemistry laboratory and then transferred into Eppendorf tubes and stored at -80°C in a deep freezer until the day of analysis. NGAL levels were measured using an ELISA (Enzyme-Linked ImmunoSorbent Assay) method with a commercial kit (USCN, China) at the Biochemistry Laboratory of Ankara Bilkent City Hospital. Each sample was measured in duplicate, and the mean values were used for evaluation. The intra-assay and inter-assay coefficients of variation (CV%) for the kit were determined to be <10% and <12%, respectively. At the 4th postoperative hour, blood samples were also analyzed for BUN, creatinine, and GFR levels, which were recorded accordingly.

Study Type

Observational

Enrollment (Estimated)

46

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Preeclamptic pregnant women aged 18 to 45 years, classified as ASA II-III, who volunteered to participate, were scheduled for cesarean section, and received spinal anesthesia were included in the study.

Description

Inclusion Criteria:

  • Patients classified as ASA physical status II-III
  • Pregnant women aged 18-45 years, diagnosed with preeclampsia and scheduled for elective cesarean section, will be included in the study.

Exclusion Criteria:

  • Patients who are unable to read, understand, or sign the informed consent form
  • Patients with a diagnosed renal disease
  • Patients who do not wish to participate in the study
  • Patients with ASA physical status greater than III
  • Patients younger than 18 or older than 45 years
  • Patients requiring sedation or undergoing general anesthesia
  • Patients with cardiac instability
  • Patients with known arrhythmias

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
CASE GROUP
During the operation, heart rate (HR) and peripheral oxygen saturation (SpO₂) were continuously monitored. Systolic arterial pressure (SAP), diastolic arterial pressure (DAP), and mean arterial pressure (MAP) were measured and recorded every 2 minutes for the first 15 minutes, then every 5 minutes thereafter. Hypotension was defined as a ≥30% decrease in MAP from baseline or systolic blood pressure <100 mmHg. Patients who developed hypotension within the first four measurements were included in the hypotension group. Patients who developed hypotension in later measurements were excluded from the study to avoid confusion with bleeding-related hypotension. A 5 mg bolus of ephedrine was administered to raise the MAP to 80% or more of the baseline level within 60 seconds. Surgical duration, amount of fluids administered, duration and number of hypotensive episodes, total dose of ephedrine, estimated blood loss, use of additional uterotonics or tranexamic acid, neonatal weight, and Apgar.
CONTROL GROUP
During the operation, the patient's heart rate (HR) and peripheral oxygen saturation (SpO₂) were continuously monitored. Systolic arterial pressure (SAP), diastolic arterial pressure (DAP), and mean arterial pressure (MAP) were measured and recorded every 2 minutes for the first 15 minutes, and then every 5 minutes thereafter. Patients whose MAP did not decrease by 30% or more from the baseline value were considered the control group

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ID: TABED 2/170/2024 Change in Plasma NGAL Levels Before and After Spinal Anesthesia
Time Frame: Before spinal anesthesia and at postoperative 4th hour
To assess whether spinal anesthesia-induced hypotension in preeclamptic patients leads to early kidney injury, based on changes in plasma NGAL (neutrophil gelatinase-associated lipocalin) levels.
Before spinal anesthesia and at postoperative 4th hour

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Renal Function Parameters Post-Spinal Anesthesia
Time Frame: Postoperative 4th hour
Evaluation of postoperative serum urea levels to assess renal function in the early postoperative period.
Postoperative 4th hour
Comparative Timing of NGAL and Creatinine in Detecting AKI
Time Frame: NGAL measured before and 4 hours after anesthesia; creatinine at 4 hours
To compare the timing of elevation between plasma NGAL and serum creatinine for early detection of acute kidney injury in preeclamptic patients.
NGAL measured before and 4 hours after anesthesia; creatinine at 4 hours
Intraoperative Hemodynamic Monitoring
Time Frame: Measurements recorded at 2, 4, 6, 8, 10, 12, 14, 20, 25, 30, 35, 40, 50, and 55 minutes after spinal anesthesia initiation.
Measurement of hemodynamic parameter systolic arterial pressure [SAP] at specified time points during the operation to evaluate the cardiovascular effects of spinal anesthesia in preeclamptic patients.
Measurements recorded at 2, 4, 6, 8, 10, 12, 14, 20, 25, 30, 35, 40, 50, and 55 minutes after spinal anesthesia initiation.
Intraoperative Hemodynamic Monitoring
Time Frame: Measurements recorded at 2, 4, 6, 8, 10, 12, 14, 20, 25, 30, 35, 40, 50, and 55 minutes after spinal anesthesia initiation.
Measurement of hemodynamic parameter diastolic arterial pressure [DAP] at specified time points during the operation to evaluate the cardiovascular effects of spinal anesthesia in preeclamptic patients.
Measurements recorded at 2, 4, 6, 8, 10, 12, 14, 20, 25, 30, 35, 40, 50, and 55 minutes after spinal anesthesia initiation.
Intraoperative Hemodynamic Monitoring
Time Frame: Measurements recorded at 2, 4, 6, 8, 10, 12, 14, 20, 25, 30, 35, 40, 50, and 55 minutes after spinal anesthesia initiation.
Measurement of hemodynamic parameter mean arterial pressure [MAP] at specified time points during the operation to evaluate the cardiovascular effects of spinal anesthesia in preeclamptic patients.
Measurements recorded at 2, 4, 6, 8, 10, 12, 14, 20, 25, 30, 35, 40, 50, and 55 minutes after spinal anesthesia initiation.
Intraoperative Hemodynamic Monitoring
Time Frame: Measurements recorded at 2, 4, 6, 8, 10, 12, 14, 20, 25, 30, 35, 40, 50, and 55 minutes after spinal anesthesia initiation.
Measurement of hemodynamic parameter heart rate [HR] at specified time points during the operation to evaluate the cardiovascular effects of spinal anesthesia in preeclamptic patients.
Measurements recorded at 2, 4, 6, 8, 10, 12, 14, 20, 25, 30, 35, 40, 50, and 55 minutes after spinal anesthesia initiation.
Intraoperative Hemodynamic Monitoring
Time Frame: Measurements recorded at 2, 4, 6, 8, 10, 12, 14, 20, 25, 30, 35, 40, 50, and 55 minutes after spinal anesthesia initiation.
Measurement of hemodynamic parameter oxygen saturation [SpO₂] at specified time points during the operation to evaluate the cardiovascular effects of spinal anesthesia in preeclamptic patients.
Measurements recorded at 2, 4, 6, 8, 10, 12, 14, 20, 25, 30, 35, 40, 50, and 55 minutes after spinal anesthesia initiation.
Renal Function Parameters Post-Spinal Anesthesia
Time Frame: Postoperative 4th hour
Evaluation of postoperative serum creatinine levels to assess renal function in the early postoperative period.
Postoperative 4th hour
Renal Function Parameters Post-Spinal Anesthesia
Time Frame: Postoperative 4th hour
Evaluation of postoperative eGFR levels to assess renal function in the early postoperative period.
Postoperative 4th hour

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Spinal Anesthesia-Related Hypotension
Time Frame: Within the first 30 minutes after spinal anesthesia
Number and percentage of patients who experience hypotension (defined as a >20% decrease from baseline systolic blood pressure) following spinal anesthesia.
Within the first 30 minutes after spinal anesthesia
Total Intraoperative Vasopressor Requirement
Time Frame: Intraoperative period
otal dose of vasopressors (e.g., ephedrine or phenylephrine) administered to treat spinal-induced hypotension.
Intraoperative period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Nihan Aydın Güzey, Ankara City Hospital Bilkent

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 8, 2025

Primary Completion (Estimated)

September 22, 2025

Study Completion (Estimated)

October 20, 2025

Study Registration Dates

First Submitted

May 26, 2025

First Submitted That Met QC Criteria

June 8, 2025

First Posted (Actual)

June 11, 2025

Study Record Updates

Last Update Posted (Actual)

June 11, 2025

Last Update Submitted That Met QC Criteria

June 8, 2025

Last Verified

June 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anesthesia

Subscribe